Last reviewed · How we verify

Reglan — Competitive Intelligence Brief

Reglan (METOCLOPRAMIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine-2 Receptor Antagonist. Area: Metabolic.

marketed Dopamine-2 Receptor Antagonist D(3) dopamine receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Reglan (METOCLOPRAMIDE) — Hikma.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Reglan TARGET METOCLOPRAMIDE Hikma marketed Dopamine-2 Receptor Antagonist D(3) dopamine receptor 1979-01-01
Pramipexole (Mirapex) Pramipexole (Mirapex) Massachusetts General Hospital marketed Dopamine agonist D2 dopamine receptor, D3 dopamine receptor
Barhemsys AMISULPRIDE Acacia marketed Dopamine-2 Receptor Antagonist [EPC] D(2) dopamine receptor 2020-01-01
Inapsine DROPERIDOL Rising marketed Dopamine-2 Receptor Antagonist [EPC] D(2) dopamine receptor 1970-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine-2 Receptor Antagonist class)

  1. Hikma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reglan — Competitive Intelligence Brief. https://druglandscape.com/ci/metoclopramide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: